Response to Miller et al: resistant mutations in CML and Ph(+) ALL - role of ponatinib.

about

Response to Miller et al: resistant mutations in CML and Ph(+) ALL - role of ponatinib.

Item

http://www.wikidata.org/entity/Q43162253

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Response to Miller et al: resistant mutations in CML and Ph

@nl

Response to Miller et al: resistant mutations in CML and Ph(+) ALL - role of ponatinib.

@en

type

Item

label

Response to Miller et al: resistant mutations in CML and Ph

@nl

Response to Miller et al: resistant mutations in CML and Ph(+) ALL - role of ponatinib.

@en

prefLabel

Response to Miller et al: resistant mutations in CML and Ph

@nl

Response to Miller et al: resistant mutations in CML and Ph(+) ALL - role of ponatinib.

@en

P1476

Response to Miller et al: resistant mutations in CML and Ph(+) ALL - role of ponatinib.

@en

P2093

Ewa Matczak

http://www.w3.org/2001/XMLSchema#string

Geeta Devgan

http://www.w3.org/2001/XMLSchema#string

Mabel Woloj

http://www.w3.org/2001/XMLSchema#string

Mark Shapiro

http://www.w3.org/2001/XMLSchema#string

Nathalie Bardy-Bouxin

http://www.w3.org/2001/XMLSchema#string

P2860

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

Resistant mutations in CML and Ph(+)ALL - role of ponatinib.

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

Strategies to circumvent the T315I gatekeeper mutation in the Bcr-Abl tyrosine kinase.

Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia.

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.

P304

23-24

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/BTT.S79507

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25733805

http://www.w3.org/2001/XMLSchema#string

P932

4340369

http://www.w3.org/2001/XMLSchema#string